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ABSTRACT: Deficiency of the lysosomal glycoside hydrolase
glucocerebrosidase (GCase) leads to abnormal accumulation
of glucosyl ceramide in lysosomes and the development of the
lysosomal storage disease known as Gaucher’s disease. More
recently, mutations in the GBA1 gene that encodes GCase
have been uncovered as a major genetic risk factor for
Parkinson’s disease (PD). Current therapeutic strategies to
increase GCase activity in lysosomes involve enzyme
replacement therapy (ERT) and molecular chaperone therapy.
One challenge associated with developing and optimizing these
therapies is the difficulty in determining levels of GCase
activity present within the lysosomes of live cells. Indeed,
visualizing the activity of endogenous levels of any glycoside hydrolases, including GCase, has proven problematic within live
mammalian cells. Here we describe the successful modular design and synthesis of fluorescence-quenched substrates for GCase.
The selection of a suitable fluorophore and quencher pair permits the generation of substrates that allow convenient time-
dependent monitoring of endogenous GCase activity within cells as well as localization of activity within lysosomes. These
efficiently quenched (∼99.9%) fluorescent substrates also permit assessment of GCase inhibition in live cells by either confocal
microscopy or high content imaging. Such substrates should enable improved understanding of GCase in situ as well the
optimization of small-molecule chaperones for this enzyme. These findings also suggest routes to generate fluorescence-
quenched substrates for other mammalian glycoside hydrolases for use in live cell imaging.
■ INTRODUCTION
Acid β-glucosidase (GCase) is a lysosomal lipid hydrolase, a
membrane-associated glycoprotein that cleaves glucosylcera-
mide (GlcCer) into glucose and ceramide.1 GCase is a member
of CAZy glycoside hydrolase family GH30 (for a description of
the CAZy classification system, see www.cazy.org and ref 1).
Homozygous loss-of-function mutations2,3 in the gene
encoding GCase (GBA1) cause Gaucher’s disease (GD), a
lysosomal storage disorder with a recessive pattern of
inheritance. There are more than 280 known mutations,
though the variation in disease penetrance is widely
heterogeneous even among identical twins.4 Most of these
mutations lead to single amino acid changes, and the resulting
mutant enzymes typically have some residual activity. The
resulting decreased GCase activity within humans causes the
detrimental accumulation of glucosylceramide within the
lysosomes of affected tissues, which is what drives GD and is
a key pathological feature of this illness. GD has been classified
into three types.5 Non-neuronopathic (type 1 GD) is the most
common of these types, affecting 1 in 10 000 within the general
population. Neuronopathic GD includes types 2 and 3, both of
which are fatal. Type 2 is more severe than type 3, exhibiting
central nervous system (CNS) involvement that manifests
within a year of birth. Type 3 GD is milder and manifests later
in life but still usually leads to death by the age of 30.
Two different types of treatments have been introduced for
type 1 GD. One is enzyme replacement therapy (ERT),6 which
is based on chronic intravenous administration of recombinant
GCase. The other is substrate reduction therapy (SRT),7 which
is based on chronic oral administration of an inhibitor of
glucosylceramide synthase, which is the enzyme catalyzing the
formation of glucosylceramide. Over the past decade an
alternative experimental approach called chaperone therapy
has gained increasing attention.8,9
Most mutations in the GBA1 gene lead to expression of
unstable mutant forms of GCase, which do not reach the
lysosome and instead undergo endoplasmic reticulum-associ-
ated degradation (ERAD). As a result, levels of active GCase
within lysosomes are diminished in those individuals carrying
such mutant GBA1 alleles. However, small-molecule ligands of
GCase that are inhibitors have been shown to serve as
chaperones that can stabilize mutant GCase, helping it to pass
quality control and reach lysosomes. After diffusion of the
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inhibitor out of the cell, chaperoned mutant GCase within
lysosomes is stable and functional. A benefit of this approach is
that, unlike recombinant enzyme delivered intravenously, such
small-molecule chaperones are brain-penetrant and might
therefore be of benefit in neuronopathic Gaucher’s disease.
Mutations in GBA1 have also been implicated in Lewy body
diseases (LBDs) such as Parkinson’s disease (PD).10−12
Unexpectedly, mutations in GBA1 have emerged in the past
few years as a major genetic risk factor for PD13−15 and have
been shown to exacerbate the progression of disease.14,16
Furthermore, PD patients, regardless of whether they carry
mutations in GCase, appear to have lower GCase activity in the
central nervous system.17,18 Recent data in which transgenic
overexpression of GCase in a PD mouse model reduced Lewy
body pathology have suggested that loss of function of GCase
contributes to α-synuclein toxicity.19,20 Accordingly, there is
great interest in developing approaches, including chaperone
therapy,21 to enhance the activity of GCase within cells, since
this may enable the development of a disease-modifying
therapy for both GD and PD.
Generally, the efficiency of inhibitory chaperones for GCase
is established by monitoring increases in the levels of this
enzyme by immunoblotting of cell lysates.9,22−24 One difficulty
within the field, however, is that there are few methods to
visualize and quantify the effects of pharmacological chaperones
directly in living cells. The need for such a method is notable
for GCase because inhibitory chaperones may persist in cells,
inhibiting GCase activity within lysosomes despite there being
increased GCase present as assessed by immunoblot analyses.
Moreover, the ability to visualize the localization of GCase
activity following administration of chaperones could help in
monitoring trafficking of the active form of this enzyme.
Accordingly, there is a need for methods to monitor GCase
activity in live cells.
Fluorogenic substrates for GCase have been described and
used to quantify GCase activity,25,26 but these have not proven
useful for direct monitoring of active enzyme by live cell
imaging. Recently, Overkleeft and co-workers described an
elegant approach27 using activity-based probes (ABPs) to
monitor total levels of active GCase enzyme in cell lysates and
even to image functional GCase within fixed cells. Though
exquisitely sensitive, one limitation to using such covalent
inactivators to monitor GCase activity is that these probes lead
to complete inactivation of GCase over time, even in the
presence of enzyme modulators including competitive inhib-
itors. Therefore, inspired by the studies by Overkleeft and co-
workers on inactivators of GCase, we set out to design a
fluorescence-quenched substrate that would enable us to
monitor not the total level of GCase in cells but rather the
amount of GCase activity present within live cells. Such
substrates could therefore prove to be valuable for monitoring
the in situ activity of GCase directly within cells in the presence
of modulators. Though fluorogenic substrates exist to monitor
abundantly expressed marker glycosidases such as Escherichia
coli and scenescence-associated β-galactosidase,28−31 to the best
of our knowledge, no substrate has been developed for
mammalian glycoside hydrolases that enables quantitative
imaging of normal endogenous levels of enzymatic activity
within live mammalian cells.
Given that fluorescence-quenched substrates of proteases are
proving to be powerful tools to study their function in live
cells,32−35 we considered various designs for fluorescence-
quenched substrates for GCase. However, the design of
fluorescence-quenched, or fluorescence resonance energy
transfer (FRET)-based, glycoside hydrolase probes is more
problematic than for proteases and is lagging behind. This
difficulty in creating such substrates for glycoside hydrolases
stems from the pocket-shaped topology of the active site of exo-
glycoside hydrolases as compared to the cleftlike architecture
found for proteases. The constrained active-site architecture
therefore makes it difficult to design glycoside hydrolase
substrates in which such groups are appropriately positioned.
Though the topic of fluorescence-quenched substrates for
glycoside hydrolases is gaining attention, current efforts have
not proven useful for monitoring the endogenous activity of
any glycoside hydrolase in mammalian cells. Furthermore,
initial efforts have yielded probes that can also inactivate the
enzyme of interest due to formation of a transient reactive
quinine methide intermediate within the enzyme active site.36,37
Accordingly, we felt that a fluorescence-quenched GCase
substrate, which would enable the enzyme to turn over
multiple molecules, could prove generally useful to assess the
enzymatic activity of GCase within live cells. Here we describe
the design and synthesis of an efficiently quenched fluorescent
GCase substrate that enables localization and quantification of
enzyme activity in live human cells by imaging.
■ RESULTS AND DISCUSSION
Synthesis and in Vitro Evaluation of Quenched
Substrate-Based Probes. For live cell monitoring of GCase
activity, an important criterion is that the probe should be able
to gain access to the lysosomes and have a low background
fluorescence. We therefore set out to design an efficiently
quenched fluorescent substrate that has a basic functionality
that would favor lysosomal uptake, as well as a reasonable
balance of hydrophilicity and polar functional groups that could
facilitate uptake of substrate by cells.
To satisfy these criteria, we developed a modular synthesis
that could accommodate the installation of different fluoro-
phore−quencher pairs. We noted that GCase accommodates
the long aliphatic chain of the ceramide moiety of GlcCer, the
natural substrate of GCase, which is pendent to the anomeric
center. We therefore chose to attach the quencher group to this
center, using an aliphatic spacer to avoid steric congestion close
to the active site, with the expectation that this linker and the
hydrophobic quencher would be tolerated by the enzyme.
Furthermore, it has been observed that modification to the 6-
position of glucose can be tolerated by GCase.27 We therefore
speculated that installation of a fluorophore at this position
within the substrate might be tolerated by the enzyme. By
positioning the quencher−fluorophore pair at these sites to
place them in close proximity to each other, we also anticipated
that highly efficient quenching could take place through both
contact quenching and FRET. Furthermore, by appending the
fluorophore, as opposed to the quencher, to the 6-position of
the glucopyranose ring, we anticipated that diffusion of the
fluorophore out of the lysosome would be hindered by the
highly polar pendent sugar ring (Figure 1).
The probe was assembled through the use of bifunctionalized
intermediate 7 (Scheme 1). To obtain this intermediate, we
carried out BF3·Et2O-promoted glycosylation of penta-O-acetyl
β-D-glucopyranose 3 with 3-bromopropanol, followed by
displacement of the bromide with sodium azide to afford
glycoside 4.38,39 Deacetylation, followed by regioselective
propargylation of the 6-hydroxyl using sodium hydride, then
followed by triphenylphosphine reduction of the azide
functionality, led to the desired intermediate 7. Using this
intermediate 7, we first tested the potential of this substrate
design using the readily available building blocks EDANS, 5-
[(2-azidoethyl)amino]naphthalene-1-sulfonic acid, as the fluo-
rophore and DABCYL, 4-{[4-(dimethylamino)phenyl]azo}-
benzoic acid, as the quencher. The succinimidyl ester
(DABCYL-NHS) was used to acylate the amine of intermediate
7 to obtain propargyl-functionalized 8a. Cu(I)-catalyzed
coupling of the propargyl group with EDANS azide afforded
the desired first-generation substrate 9a (Scheme 2).
With substrate 9a in hand, we evaluated its quenching
efficiency. The intact substrate shows strikingly little
fluorescence, whereas the chemically synthesized cleaved
substrate shows much greater fluorescence with a spectrum
matching that of the free fluorophore (excitation max = 338 nm
and emission max = 490 nm; Figure S3, Supporting
Information). We calculated that quenching is 97.6% efficient
for this substrate at the concentrations used for in vitro assays
(Figure S5, Supporting Information), which supports this probe
design being effective for dark-to-light switching. We next
evaluated the processing of this substrate by GCase in vitro.
Because probe 9a shows limited solubility, we were unable to
assess activity at concentrations higher than 200 μM,
precluding the determination of a Km value. Because Km is a
composite rate constant, we assayed substrate 9a as a
competitive inhibitor of GCase in order to determine whether
it might bind more tightly to the enzyme than the Km suggests.
We find no sign of saturation of the enzyme up to 100 μM
(data not shown), which is consistent with the Michaelis−
Menten analysis described just above. Nevertheless, we were
able to establish the second-order rate constant for cleavage of
this substrate, kcat/Km = 60 ± 2 min
−1·mM−1, which is 2.9-fold
poorer than that of the widely used GCase substrate 4-
methylumbelliferyl β-D-glucopyranoside (4-MUGlc), kcat/Km =
176 ± 2 min−1·mM−1 (Figure S7, Supporting Information).
With the realization that this probe design is suitable for
generating fluorescence-quenched GCase substrates, we next
set out to develop a second-generation probe that could be
used for live cell imaging. Because probe 9a fluoresces with an
emission maximum at 490 nm, we found it incompatible for use
in live cell imaging due to endogenous cellular fluorescence at
this wavelength. We therefore turned to using boron−
dipyrromethene (BODIPY) 576/589, which would enable
using a more red-shifted laser that would limit damage to cells
during imaging as well as reducing autofluorescence from cells.
We selected Black Hole Quencher 2 (BHQ2) as the quencher
because its absorption band overlaps effectively with the
emission band of BODIPY 576/589, suggesting FRET-based
quenching should be efficient. Moreover, we reasoned that the
mildly basic aniline within the substrate would favor its
accumulation within the acidic environment of lysosomes. The
BHQ2 carboxylic acid succinimidyl ester (BHQ2-NHS)
quencher was therefore first coupled to the amine by an
amide coupling reaction to afford 8b.
To keep the sugar scaffold the same as in substrate 9a, we
first attached a BocNHCH2CH2N3 linker.
40 Copper(I)
catalyzed azide−alkyne cycloaddition reaction (CuAAC) with
BocNHCH2CH2N3 yielded the terminal Boc-protected amine.
After removal of the tert-butyloxycarbonyl (Boc) protecting
group, the resulting amine intermediate was reacted with the N-
hydroxysuccinimide ester of BODIPY 576/589 (BODIPY-
NHS) to furnish the second-generation substrate 9b (Scheme
2). We found the excitation and emission maxima for 9b were
574 and 595 nm, respectively (Figure S4, Supporting
Information). Notably, substrate 9b showed 99.9% quenching
efficiency (Figure S6, Supporting Information) and was
processed in vitro by GCase (Figure S8, Supporting
Information) 2.2-fold worse than substrate 9a.
Live Cell Imaging of GCase Activity in Human
Fibroblasts. With probe 9b in hand, we evaluated whether
time- and dose-dependent processing of substrate could be
Figure 1. Design of fluorescence-quenched GCase substrate and
known GCase inhibitors used in this study. (A) General reaction
scheme showing the design for fluorescence-quenched GCase
substrates. (B) Proposed structure of GCase inhibitory chaperone
AT3375 1 and the structure of inactivator conduritol B epoxide (CBE)
2.
Scheme 1. Synthesis of Amine Intermediate 7a
a(a) (i) 3-Br-propanol, BF3·Et2O, 60%; (ii) NaN3, DMF, 80 °C; 70%.
(b) Cat. K2CO3, MeOH, quantitative. (c) NaH, propargyl bromide, 0
°C, 40%. (d) TPP, Et2O, H2O, 60%.
Scheme 2. Synthesis of Fluorescent Quenched Substrates 9a
and 9ba
aFor 8a: (a) DABCYL-NHS, DIPEA, DMF, quantitative. For 8b: (a)
BHQ2-NHS, DIPEA, DMF, quantitative. For 9a: (b) EDANS-N3,
NaAsc., CuSO4, DCM/H2O (1:1), 50%. For 9b: (b) (i)
N3CH2CH2NHBoc, sodium ascorbate, CuSO4, DCM/H2O (1:1),
50%; (ii) 90% TFA in DCM at 0°C, quantitative; (iii) BODIPY-NHS,
DIPEA, DMF, 80%.
observed in human primary skin fibroblasts. High content
imaging of cells treated with 4′,6-diamidino-2-phenylindole
(DAPI), to stain nuclei, and 5 μM substrate 9b revealed
increasing fluorescence as a function of time (Figure 2A). The
fluorescence associated with cleavage of probe 9b was present
in a punctate pattern consistent with a lysosomal distribution.
By integrating the fluorescence intensity from randomly
selected fields, we observed a quantitative increase in
fluorescence as a function of time (Figure 2B). We next
examined the dose-dependent cellular fluorescence of probe 9b
(Figure 2C) and observed a linear increase in fluorescence that
depended on the concentration of 9b (Figure 2D). As assessed
by the trypan blue assay, we observed no toxicity associated
with the probe upon incubating cells for 3−20 h (data not
shown). While these data reveal probe 9b is processed in cells
to result in the fluorescent product, we sought to test whether
the observed fluorescence was dependent on GCase activity.
To assess whether the punctuate fluorescence observed is
distributed in lysosomes, we carried out colocalization experi-
ments using LysoTracker Green DND-26, which is a widely
used lysosomal marker compatible with live cell imaging. We
therefore treated cells with substrate 9b for 3 h, after which
LysoTracker Green was added to the culture for 15 min before
imaging by confocal microscopy. We observed extensive
superposition of substrate 9b-associated fluorescence and
LysoTracker Green fluorescence (Figure 3), indicating that
the fluorescence associated with cleavage of 9b occurs in the
lysosomal compartments of the cells. Analysis of the Z-
direction stack also indicated substrate processing was
occurring within lysosomes (Figure 3B).
Within human cells there are three β-glucosidases, including
GBA221 from family GH116 and GBA322 from family GH1,
which respectively have membrane and cytosolic localizations.
Those enzymes can be distinguished from GCase on the basis
of their localization but also because they are relatively
insensitive to conduritol B epoxide (CBE), whereas lysosomal
GCase is quickly inactivated by CBE.27,43,44 Therefore, to
explore the in-cell specificity of substrate 9b toward GCase, we
incubated cells with CBE or vehicle alone for 16 h, then treated
the cells with both substrate 9b and DAPI for 2 h. We then
imaged cells by high content imaging (Figure 4) as a function
of cell concentration. The analysis of different cell densities
indicates the high content imaging assay does not show
significant variability as a function of the number of cells plated
within the range used here. We found that CBE-treated cells
showed little fluorescence as compared to vehicle-treated
control cells (Figure 4). We also evaluated substrate 9b in a
human neuronal cell culture model, SK-N-SH neuroblastoma
cells, and found that this substrate was processed within these
cells in a similar manner (Figure S9, Supporting Information),
indicating that such substrates should prove useful in various
cell types. These data indicate that probe 9b is predominantly
processed by GCase within cells, supporting its use as a tool to
image GCase activity within live cells across a range of cell
densities.
Finally, to assess whether substrate 9b can be used to
quantify chaperoning of wild-type GCase, we used the
inhibitory GCase chaperone AT3375, for which the proposed
structure is shown in Figure 1.45 We treated cells with AT3375
as has been previously described for isofagomine26 to induce
chaperoning of wild-type GCase. Treating cells for 5 days with
AT3375, washing cells overnight with fresh medium, and then
incubating with substrate 9b for 3 h resulted in a 1.4-fold
increase in processing of substrate 9b as observed by
fluorescence microscopy (Figure 5). This increase in cleavage
of substrate 9b is consistent with previous results for use of
Figure 2. Time- and dose-dependent increases in fluorescence upon
incubation of GCase fluorescence-quenched substrate 9b with human
fibroblasts. (A) Representative images showing that incubation with
substrate 9b (5 μM) leads to time-dependent increases in fluorescence
observed within primary human fibroblasts. (B) Quantitative relative
fluorescence intensity per cell at various time points to 4 h reveals a
linear increase in signal as a function of time. (C) Representative
images showing that fluorescence intensity within human fibroblasts,
observed after 2 h of incubation with fluorescence-quenched probe 9b,
increases with increasing probe concentration. (D) Quantitative
relative fluorescence intensity per cell at various concentrations of
fluorescence-quenched substrate 9b reveals a linear increase in
fluorescence as a function of probe concentration. The blue signal in
panels A and C represents staining of nuclei with DAPI, and the red
signal represents the cleaved product of 9b. White scale bars represent
100 μm. Error bars represent the standard error of the mean obtained
from four randomly selected fields from two independent experiments.
Figure 3. Processing of fluorescence-quenched substrate 9b in
lysosomes. (A) Fluorescence images are from one Z-section selected
from the center of the stack. (Upper left) Differential interference
contrast (DIC) image; (upper right) fluorescence image (green) for
LysoTracker Green; (lower left) fluorescence image (red) for signal
from processed substrate 9b; (bottom right) merged image. (B)
Representative image showing the maximum intensity projection of Z-
sections with the vertical slice representing the yz-axis and the
horizontal slice representing the xz-axis. Scale bars represent 20 μm.
isofagomine to chaperone GCase26 in human fibroblasts.
Furthermore, we found by immunoblot assay that the levels
of GCase protein were increased upon chaperoning by AT3375
to the same extent as measured by substrate 9b (Figure 5).
These data show that live cell imaging with substrate 9b can be
used to monitor GCase activity in live cells and can be used to
quantitatively assess chaperoning of GCase.
■ CONCLUSIONS
Collectively, these studies reveal a convenient modular design
for generation of fluorescence-quenched substrates for GCase.
These substrates are very efficiently quenched when intact but
give rise to fluorescence when hydrolytically cleaved by GCase.
Substrate 9b shows greater than 99.9% quenching efficiency,
which enables direct visualization of GCase activity in live cells.
Given increasing interest in the physiological and pathophysio-
logical roles of GCase in both Gaucher’s and Parkinson’s
diseases as well as the characterization of inhibitors and
chaperones of GCase, we anticipate that substrate 9b and
analogues may find common use for those interested in
identifying GCase chaperones as well as for studying the
trafficking and regulation of GCase within cells. Additionally,
the compatibility of this approach with high content imaging in
live cells opens the door to screening for endogenous protein
modifiers of GCase activity as well as screening for activators
that function within cells to influence GCase activity.
The use of common orthogonally functionalized intermedi-
ate 7 within the synthesis also enables late installation of the
fluorophore and quencher. This flexibility opens the door to
further optimization of such GCase substrates. Through the
judicious selection of fluorophores in combination with various
imaging systems, it may be feasible to perform super-resolution
imaging of GCase activity or imaging of GCase within animal
models. More generally, to the best of our knowledge, direct
quantitative imaging of mammalian glycoside hydrolases at
normal endogenous levels has not been previously demon-
strated within live cells. Accordingly, this strategy of using
fluorescence-quenched substrates may find, by adaptation,
application for the investigation of other mammalian glycoside
hydrolases.
■ EXPERIMENTAL SECTION
General Information. 1H and 13C NMR spectra were obtained on
Bruker AVII 600 (600 MHz for 1H and 151 MHz for 13C) and Bruker
AVIII 400 (400 MHz for 1H and 101 MHz for 13C) spectrometers.
Unless stated otherwise, deuterated methanol (CD3OD) was used as
the solvent, with CH3OH (δH 3.31) or CD3OD (δC 49.00) being
employed as internal standards. Mass spectra were recorded on an
Agilent 6210 time-of-flight (TOF) liquid chromatography/mass
spectrometry (LC/MS) system. The LC system used was an Agilent
1200 HPLC, and the MS was a 6210 high-resolution TOF MS. A
Bruker maXis impact quadrupole TOF LC/MS system was also used.
This system consists of an Agilent 1200 HPLC and a Bruker maXis
impact ultra-high resolution tandem TOF MS. The ionization mode
used was positive electrospray ionization (+ESI). Flash chromatog-
raphy was performed on BDH silica gel or Geduran silica gel 60 with
the specified solvents. Thin-layer chromatography (TLC) was
performed on Merck silica gel 60 F254 aluminum-backed plates that
were stained by heating (≥200 °C) with 5% sulfuric acid in EtOH.
Percentage yields for chemical reactions are quoted only for those
compounds that were purified by recrystallization or by column
chromatography and for which the purity was assessed and verified by
1H NMR spectroscopy. Chemicals and solvents were obtained from
Sigma−Aldrich and used without further purification unless otherwise
noted. EDANS and DABCYL-NHS ester were purchased from
AnaSpec. Inc.; BHQ2 was obtained from Biosearch Technologies;
and BODIPY576/589, LysoTracker Green DND-26, and α-minimum
Figure 4. GCase-dependent processing of fluorescence-quenched substrate 9b. (A) Representative images showing that treatment of fibroblasts with
CBE (2) leads to decreased fluorescence associated with processing of fluorescence-quenched substrate 9b within human fibroblasts. The upper line
of images in panel A are fluorescence images obtained in the absence of CBE, and the bottom row are fluorescence images obtained in the presence
of CBE. (B) Quantitative relative fluorescence intensity per cell for cells treated with substrate 9b and substrate 9b plus CBE at different
concentrations of cells in each well. White scale bars represent 100 μm.
Figure 5. Incubation of fibroblasts with the chemical chaperone
AT3375 (10 μM) for 5 days, followed by 1 day washout, results in
increased GCase activity and protein. (A) Representative images
showing that chaperoning with AT3375 leads to increased GCase
activity relative to control, as reflected in the extent of turnover of
substrate 9b (5 μM). CBE treatment reduces GCase activity. (B)
Quantitative relative fluorescence intensity per cell for cells treated
with substrate 9b, substrate 9b plus CBE, and AT3375 for 5 days
followed by washout for 1 day. (C) Immunoblot analysis shows that
chaperoning with AT3375 for 5 days leads to an increase in GCase
protein levels. (D) Quantitative relative immunoreactivity for GCase
levels in cells treated with AT3375 or vehicle alone as assessed by
immunoblot. Scale bars represent 50 μm.
essential medium (α-MEM, without nucleosides) were from Life
Technologies. Liquid chromatography was performed on an Agilent
1100 series HPLC equipped with a C18 column.
Synthetic Procedures for Chemical Compounds. 3-Azido-
propyl β-D-Glucopyranoside (5). Anhydrous potassium carbonate (64
mg; 0.46 mmol) was added to a solution of 4 (2.00 g; 4.64 mmol) in
MeOH (25 mL). The reaction mixture was stirred overnight at room
temperature. TLC: Rf 0.2 in 15% MeOH in CHCl3. After the reaction
was juged complete by TLC, the mixture was concentrated and 5 was
purified by silica gel column chromatography and eluted with 12%
MeOH in CHCl3 to give a viscous liquid: yield 95%, 1.2 g. High-
resolution mass spectrometry (HRMS) [M + Na]+ calcd 286.10096,
found 286.10090. 1H NMR (600 MHz, MeOD) δ 1.87 (p, J = 6.5 Hz,
2H), 3.17 (dd, J = 9.1, 7.9 Hz, 1H), 3.29−3.24 (m, 2H), 3.35 (m, 1H)
3.45 (t, J = 6.6 Hz, 2H), 3.65 (ddd, J = 12.3, 11.1, 5.7 Hz, 2H), 3.88−
3.83 (m, 1H), 3.97 (dt, J = 10.1, 6.0 Hz, 1H), 4.25 (d, J = 7.8 Hz, 1H).
13C NMR (151 MHz, MeOD) δ 104.45, 78.07, 77.95, 75.11, 71.65,
67.57, 62.76, 49.43, 30.26.
3-Azidopropyl-6-O-propargyl β-D-Glucopyranoside (6). To a
solution of 5 (193 mg, 0.73 mmol) in anhydrous N,N-dimethylforma-
mide (DMF, 5 mL) at 0 °C was added a 60% dispersion of NaH (132
mg; 3.30 mmol) in mineral oil, and the mixture was stirred for 5 min.
Propargyl bromide (109 mg, 0.73 mmol) was then added dropwise to
the mixture, and stirring was continued for 30 min. TLC: Rf 0.3 in 10%
MeOH in CHCl3. After the reaction was judged complete, water was
added and the mixture was extracted with ethyl acetate, dried over
Na2SO4, and concentrated. Compound 6 was purified by silica gel
column chromatography and eluted with 5% MeOH in CHCl3: yield
40%, 88 mg. HRMS [M + H]+ calcd 302.13466, found 302.13386. 1H
NMR (600 MHz, MeOD) δ 1.92−1.81 (m, 2H), 2.84 (t, J = 2.4 Hz,
1H), 3.20−3.14 (m, 1H), 3.30−3.26 (m, 1H), 3.34 (d, J = 7.9 Hz,
1H), 3.42−3.37 (m, 1H), 3.45 (t, J = 5.1 Hz, 2H), 3.70−3.60 (m, 2H),
3.95−3.85 (m, 2H), 4.27−4.17 (m, 3H). 13C NMR (151 MHz,
MeOD) δ 102.50, 78.60, 76.02, 74.80, 73.91, 73.02, 69.64, 68.30,
65.72, 57.46, 28.31.
3-Amido-DABCYL-6-O-propargyl β-D-Glucopyranoside (8a). To a
mixture of anhydrous diethyl ether (3 mL) containing anhydrous
tetrahydrofuran (THF, 1 mL) and 6 (40 mg; 0.13 mmol) was added
triphenylphosphine (TPP) (87 mg, 0.32 mmol). The reaction mixture
was stirred at room temperature for 3 h, after which H2O (0.3 mL)
was added and the mixture was allowed to stir overnight. TLC: Rf 0.2
in EtOAc/MeOH/H2O (3:2:1). The reaction mixture was concen-
trated after being judged complete by TLC and then resuspended in
water and extracted with CHCl3 (3×). The aqueous layer was
concentrated and loaded on a short column of silica gel, and the
desired intermediate was eluted with EtOAc/MeOH/H2O (3:2:1)
containing 4% aqueous ammonia to furnish crude amine (7). This
crude amine was used immediately without further purification. HRMS
[M + H]+ calcd 276.14416, found 276.14376.
To this crude amine 7 (48 mg, 0.174 mmol) in anhydrous DMF (1
mL) was added DABCYL-NHS (70 mg, 0.192 mmol) and N,N-
diisopropylethylamine (DIPEA, 30 μL, 0.17 mmol). The reaction
mixture was stirred overnight at room temperature in the dark. TLC:
Rf 0.5 in 10% MeOH in CHCl3. After being judged complete by TLC,
the mixture was concentrated and 8a was purified by silica gel column
chromatography and eluted with 5% MeOH in CHCl3: yield 90%, 83
mg. HRMS [M + H]+ calcd: 527.25003, found 527.25021. 1H NMR
(400 MHz, MeOD) δ 2.00−1.89 (m, 2H), 2.82 (q, J = 2.8 Hz, 1H),
3.11 (s, 6H), 3.21 (dd, J = 9.0, 7.9 Hz, 1H), 3.37−3.33 (m, 1H), 3.47−
3.39 (m, 1H), 3.59−3.52 (m, 2H), 3.76−3.63 (m, 2H), 3.90−3.84 (m,
1H), 3.99 (dt, J = 10.0, 5.9 Hz, 1H), 4.17 (dd, J = 4.1, 2.4 Hz, 2H),
4.30 (d, J = 7.8 Hz, 1H), 6.86−6.79 (m, 2H), 7.88−7.81 (m, 4H),
7.97−7.91 (m, 2H). 13C NMR (101 MHz, MeOD) δ 169.61, 156.38,
154.65, 144.84, 135.95, 129.28, 126.39, 122.97, 112.62, 104.55, 80.54,
78.02, 76.74, 75.99, 75.11, 71.64, 70.28, 68.94, 59.40, 40.38, 38.54,
30.39.
3-Amido-DABCYL-6-methoxytriazol-EDANS β-D-Glucopyranoside
(9a). To a mixture of 8a (40 mg, 0.076 mmol) and EDANS-azide (53
mg, 0.18 mmol) in H2O/dichloromethane (DCM) (1.5 mL/1.5 mL)
were added sodium ascorbate (45 mg; 0.2277 mmol) and CuSO4·
5H2O (28 mg; 0.11 mmol). The mixture was stirred overnight at room
temperature in the dark. TLC: Rf 0.1 in 20% MeOH in CHCl3. The
reaction mixture was concentrated and the desired material was
purified by reverse-phase HPLC. Elution was performed with a
gradient of 20−24% acetonitrile (with 0.1% trifluoroacetic acid, TFA)
in H2O (with 0.1% TFA) over 55 min. The fractions collected from 46
to 48 min afforded pure 9a (Figure S1, Supporting Information): yield
50%, 31 mg. HRMS [M + H]+ calcd 819.31304, found 819.31359. 1H
NMR (601 MHz, MeOD) δ 1.92−1.80 (m, 2H), 3.09 (s, 6H), 3.13
(dt, J = 9.2, 6.9 Hz, 1H), 3.20−3.17 (m, 1H), 3.38−3.32 (m, 2H), 3.42
(dt, J = 3.3, 1.6 Hz, 1H), 3.52−3.45 (m, 2H), 3.58 (dd, J = 10.7, 5.4
Hz, 1H), 3.67−3.60 (m, 1H), 3.78−3.70 (m, 3H), 3.87−3.81 (m, 1H),
4.23 (d, J = 7.8 Hz, 1H), 4.57 (s, 2H), 4.66 (d, J = 6.0 Hz, 2H), 6.61 (t,
J = 7.5 Hz, 1H), 6.81 (d, J = 9.2 Hz, 2H), 7.36 (dq, J = 16.4, 8.2 Hz,
2H), 7.82−7.77 (m, 3H), 7.84 (d, J = 9.1 Hz, 2H), 7.92 (d, J = 8.5 Hz,
2H), 8.03 (t, J = 8.8 Hz, 1H), 8.13 (t, J = 8.0 Hz, 1H), 8.20 (t, J = 7.1
Hz, 1H). 13C NMR (151 MHz, MeOD) δ 169.49, 156.35, 154.65,
145.79, 144.83, 144.49, 142.13, 131.59, 129.31, 128.39, 126.79, 126.39,
125.78, 125.18, 123.82, 122.90, 117.10, 112.63, 105.26. 104.53, 77.95,
76.92, 75.10, 71.48, 70.49, 69.04, 65.23, 50.24, 44.74, 40.37, 38.63,
30.30.
3-Amido-BHQ2-6-O-propargyl β-D-Glucopyranoside (8b). To a
mixture of 7 (2.5 mg, 0.009 mmol) and BHQ2-NHS (5 mg, 0.008
mmol) in anhydrous DMF (0.6 mL) was added diisopropylethyl
amine (1.6 μL, 0.0090 mmol). The reaction mixture was stirred
overnight in the dark at room temperature. TLC: Rf 0.5 in 10% MeOH
in CHCl3. After completion of the reaction as judged by TLC, the
mixture was concentrated and 8b was purified by silica gel column
chromatography and eluted with 8% MeOH in CHCl3: yield 90%, 6.2
mg. Low-resolution MS [M + H]+ calcd 764.3250, found 764.3241. 1H
NMR (600 MHz, MeOD) δ 1.80 (t, J = 6.0 Hz, 2H), 1.99−1.92 (m,
2H), 2.29 (t, J = 7.4 Hz, 2H), 2.85 (s, 1H), 3.12 (s, 3H), 3.21−3.15
(m, 1H), 3.54 (t, J = 7.6 Hz, 2H), 3.63 (dd, J = 24.5, 13.2 Hz, 2H),
3.93−3.83 (m, 2H), 4.02 (s, 3H), 4.06 (s, 3H), 4.22 (dd, J = 26.4, 6.1
Hz, 3H), 6.88 (d, J = 9.3 Hz, 2H), 7.49 (s, 1H), 7.55 (s, 1H), 7.90 (d, J
= 9.2 Hz, 2H), 8.10 (d, J = 8.6 Hz, 2H), 8.42 (d, J = 11.2 Hz, 2H). 13C
NMR (151 MHz, MeOD) δ 173.27, 155.74, 152.99, 151.90, 150.22,
147.99, 146.08, 143.59, 141.40, 125.23, 123.82, 122.66, 110.69, 102.39,
100.25, 99.37, 78.62, 76.03, 74.70, 74.05, 73.06, 69.64, 68.38, 66.58,
57.46, 55.32, 50.66, 47.85, 36.79, 35.76, 31.97, 28.29, 22.16.
3-Amido-BHQ2-6-methoxytriazolyl-1′-ethyl-3′-amido-BODI-
PY576/589 β-D-Glucopyranoside (9b). A suspension of 8b (3 mg;
0.004 mmol) and N3CH2CH2NHBoc in H2O/DCM (1.5 mL/1.5 mL)
was set to stir at room temperature. To this mixture were added
sodium ascorbate (2.3 mg, 0.012 mmol) and CuSO4·5H2O (1.4 mg,
0.0058 mmol), and stirring was continued overnight at room
temperature. After the reaction was judged complete by TLC, the
mixture was concentrated, filtered through a column of silica gel, and
then cooled to 0 °C after which an ice cold solution of 90% TFA in
DCM (3 mL) was added and the mixture was stirred for two hours
after which it was concentrated. The resulting solution was then
directly used for coupling with BODIPY-NHS. For the coupling of this
crude intermediate (4.5 mg, 0.0052 mmol), anhydrous DMF (0.8 mL)
was added, followed by diisopropylethyl amine (0.9 μL, 0.005 mmol)
and BODIPY-NHS (2.4 mg, 0.0057 mmol). The resulting reaction
mixture was stirred overnight in the dark. TLC: Rf 0.3 in 10% MeOH
in CHCl3. After being judged complete by TLC, the mixture was
concentrated and 9b was purified by silica gel column chromatography
and eluted with 7% MeOH in CHCl3. The material was further
purified by HPLC (Figure S2, Supporting Information): yield 60%, 2.7
mg. HRMS [M + H]+ calcd 1161.4893, found 1161.4888. 1H NMR
(600 MHz, MeOD) δ 1.76 (d, J = 6.3 Hz, 3H), 1.93 (d, J = 7.7 Hz,
2H), 2.23 (d, J = 7.2 Hz, 2H), 2.59−2.55 (m, 2H), 3.07 (s, 3H), 3.16
(t, J = 7.0 Hz, 1H), 3.21 (t, J = 7.7 Hz, 3H), 3.50−3.46 (m, 2H), 3.56
(dd, J = 10.3, 6.1 Hz, 1H), 3.66−3.60 (m, 5H), 3.77 (d, J = 12.8 Hz,
1H), 3.87−3.82 (m, 1H), 4.00 (s, 4H), 4.04 (s, 3H), 4.19 (d, J = 7.8
Hz, 1H), 4.50−4.46 (m, 2H), 4.58 (s, 2H), 6.25 (d, J = 3.9 Hz, 1H),
6.35−6.33 (m, 1H), 6.83 (d, J = 9.3 Hz, 2H), 6.88 (d, J = 4.0 Hz, 1H),
6.99 (d, J = 4.6 Hz, 1H), 7.17 (t, J = 3.9 Hz, 2H), 7.19 (s, 1H), 7.24−
7.20 (m, 1H), 7.46 (s, 1H), 7.53 (s, 1H), 7.79 (s, 1H), 7.87 (d, J = 9.2
Hz, 2H), 8.08 (d, J = 9.1 Hz, 2H), 8.40 (d, J = 9.1 Hz, 2H). 13C NMR
(151 MHz, MeOD) δ 175.40, 175.35, 157.88, 155.14, 154.03, 152.37,
150.13, 148.21, 146.05, 145.72, 143.54, 133.43, 132.40, 132.30, 125.96,
125.63, 125.01, 124.82, 121.36, 119.35, 112.84, 112.49, 104.58, 102.39,
101.49, 78.14, 77.02, 75.22, 71.69, 70.95, 68.82, 65.44, 57.45, 52.77,
50.73, 49.72, 49.15, 40.66, 38.91, 37.94, 36.22, 34.11, 33.23, 30.93,
30.47, 25.74, 24.31, 23.88.
In Vitro Kinetic Assays. In vitro GCase assays were conducted on
a Cary Eclipse fluorescence spectrophotometer (Varian Inc.). The
continuous assay was performed in citrate−phosphate buffer (20 mM,
pH 5.5) in the presence of 0.2% taurodeoxycholate at 37 °C. A buffer
having a pH of 5.5 was used because GCase shows optimal activity at
this pH, which is similar to the pH of lysosomes, the native
environment for this enzyme. Additionally, 0.2% taurodeoxycholate
was included in these assays because it has been shown this detergent
activates this normally membrane-associated enzyme.46 The concen-
trations of substrates 4-MUGlc, 9a, and 9b used were 1, 2.5, 5, 15, and
20 μM. The final volume of each assay was 160 μL containing 1%
dimethyl sulfoxide (DMSO). The reactions were initiated by the
addition of recombinant purified GCase (33.5 nM final concentration)
for 4-MUGlc and substrate 9a, whereas GCase (9.3 nM final
concentration; R&D Systems) was used for substrate 9b. The assays
were then monitored for 500 s. The instrument excitation and
emission wavelengths were set at 338 and 490 nm, respectively, for 9a
with a slit width of 5 nm. The instrument emission filter was set open,
excitation filter at auto, and the photomultiplier tube (PMT) voltage at
high. The excitation and emission wavelengths were adjusted for
substrate 9b (ex 574 and em 595 nm) and 4-MUGlc (ex 365 and em
450 nm); otherwise all other conditions were the same as described
above. Standard curves to quantify 4-MU, EDANS, and BODIPY 576/
589 releases were generated under the same conditions as the assays.
Cell Culture. Human primary fibroblast cell lines were cultured,
except where indicated otherwise, in α-MEM (without nucleosides)
supplemented with 10% fetal bovine serum (FBS) and 1% penicillin−
streptomycin at 37 °C and 5% CO2 at a density of 10 000 cells/mL.
The medium was replaced every 3−4 days and the cells were passaged
after reaching 70−80% confluency, which occurred approximately
every 2 weeks. SK-N-SH (ATCC) cells were cultured in DMEM
supplemented with 15% FBS as described above but were seeded in
quadruplicate into the central 60 wells of a glass-bottom 96-well plate
(Corning 4580).
Live Cell Imaging. Confocal fluorescence microscopy was
performed on a Nikon A1R laser scanning confocal system in
conjunction with a Nikon Eclipse Ti inverted microscope. All
fluorescence images were processed with Volocity quantification
software (PerkinElmer). For confocal imaging, fibroblasts were plated
on a 35 mm dish with a 1.5 coverglass (MatTek Corp.) in 2 mL of
complete growth medium and allowed to grow to 50% confluence.
Cells were then washed three times with phosphate-buffered saline
(PBS) warmed to 37 °C. A mixture of substrate dissolved in DMSO
(0.1% final concentration of DMSO) was added to the imaging
medium [0.2× Hank’s buffered salt solution (HBSS) containing 0.6%
glucose and 40 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid (HEPES)], which was then added to these cells and incubated at
37 °C and 5% CO2 in the dark for the times specified. The images
were collected by use of a 60× oil objective. The effect of substrate on
the viability of cells was assessed by the trypan blue assay (data not
shown) after the cells were treated with substrate for 3 and 20 h in
imaging medium. The viability of cells was affected by neither the
substrate nor the imaging medium.
To assess the effects of cell density on fluorescence per cell, 10 000,
5000, 2500, 1250, 625, and 0 cells were seeded in quadruplicate into
the central 60 wells of a glass-bottom 96-well plate (Corning 4580).
Cells were allowed to adhere, after which 1 mM CBE (Sigma) was
applied to two of the four cultures at each cell density and cells were
then cultured for 16 h. The medium from each well was then removed,
the cells were washed twice with PBS warmed to 37 °C, and the cells
were then fed with MEM containing 5 μM substrate, 1 μM DAPI (Life
Technology D3571), and 1% DMSO but lacking phenol red (Gibco
41061-029). After 2 h of incubation, the cells were washed twice with
PBS warmed to 37 °C and the cells fed with MEM medium lacking
phenol red for imaging on a Cytation 3 cell imaging multi-mode reader
(Bio-Tek) with DAPI and Cy3 channels and a 20× objective. Four
fields of images were acquired at predefined regions of each well. Data
were analyzed by determining the total fluorescence intensity obtained
from the Cy3 channel and dividing by the number of cells in an
individual field, chosen randomly from two of the fields obtained per
well. For the time-course incubation of the substrate, 5000 cells were
seeded as described above and allowed to adhere overnight. The
experiment was carried out as described above except that 5 μM
substrate in DMSO, to yield a 1% final DMSO concentration, was
added to duplicate wells at 4, 3, 2, 1, 0.5, 0.12 h prior to imaging. DAPI
(1 μM, Life Technology D3571) was added to the wells 2 h before
imaging. Imaging and quantification were performed as described
above. Dose−response studies were carried out as described above
except that duplicate wells contained 1 μM DAPI along with 0, 0.5, 1,
2.5, or 5 μM substrate and 1% DMSO. Cells were incubated for 2 h,
and imaging and quantification were performed as described above.
SK-N-SH (ATCC) cells were seeded (10 000 cells) in quadruplicate
into the central 60 wells of a glass-bottom 96-well plate (Corning
4580). These cells were handled and imaged as described above for
human fibroblasts.
Chaperoning Experiments. Primary human fibroblast cells were
plated onto 35 mm dishes containing 1.5 coverglass (MatTek Corp.)
at 15 000 cells/dish and allowed to adhere overnight. On the second
day, growth medium with or without 10 μM inhibitory chaperone
AT3375 in 0.1% DMSO final concentration was applied for 5 days. On
day 6, the cells were washed with cold PBS three times and then
replaced with fresh medium twice 4 h apart. CBE (1 mM) was added
in triplicate to control cells cultured in the absence of AT3375 and
then allowed to incubate overnight at 37 °C in the presence of 5%
CO2. Finally, the cells were washed with PBS three times and then
incubated with substrate 9b for 3 h, after which the cells were imaged
by confocal fluorescence microscopy. Z stacks of images were collected
by use of a 40× oil objective. To quantify the activity of the
fluorescence substrate, two Z-stack images were acquired from each of
three experimental replicates from separate dishes. Two consecutive
optical images from the center of the Z stack were converted into 8-bit
RGB tiff images for analysis by ImageJ software version 2.30 (NIH,
Bethesda, MD). Two regions of interest (ROI) of 4.7 μm × 4.7 μm
were defined in the cytosolic space adjacent to the cell nucleus per cell
in each image to yield a total of 20 ROI for analysis by densitometry.
Quantitative Immunoblotting. Wild-type human fibroblast cells
were cultured as described above in 6-well plates at a density of 0.5 ×
106 cells/well. Cells were treated with AT3375 at a final concentration
of 10 μM for 5 days. Cells were collected and lysed with 1% sodium
dodecyl sulfate (SDS), and then 20 μg of protein from each sample
was separated by electrophoresis on 4−15% SDS−polyacrylamide
minigels (Bio-Rad), transferred to nitrocellulose membrane (Bio-Rad),
and immunoblotted with a mouse IgG monoclonal anti-human GCase
antibody (R&D Systems) at 1:1000 dilution; rabbit anti-β-actin
antibody (LI-COR) was used as a loading control (1:10000 dilution).
Protein bands were detected with IRDye 680 conjugated goat anti-
mouse IgG and IRDye 800 conjugated goat anti-rabbit secondary
antibodies (LI-COR). The blots were scanned using a LI-COR
odyssey image system, and densitometry was performed with ImageJ
(NIH).
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